309 related articles for article (PubMed ID: 33641345)
21. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis.
Grover S; Ruan AB; Srivoleti P; Giobbie-Hurder A; Braschi-Amirfarzan M; Srivastava A; Buchbinder EI; Ott PA; Kehl KL; Awad MM; Hodi FS; Rahma OE
JCO Oncol Pract; 2020 Sep; 16(9):e933-e942. PubMed ID: 32401685
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of immune checkpoint inhibitors in patients with non-small cell lung cancer aged 80 years or older.
Saito Z; Fujita K; Okamura M; Ito T; Yamamoto Y; Kanai O; Hashimoto M; Nakatani K; Sawai S; Mio T
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1405. PubMed ID: 33934572
[TBL] [Abstract][Full Text] [Related]
23. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.
Tison A; Garaud S; Chiche L; Cornec D; Kostine M
Nat Rev Rheumatol; 2022 Nov; 18(11):641-656. PubMed ID: 36198831
[TBL] [Abstract][Full Text] [Related]
24. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
25. Multidisciplinary approach to treatment with immune checkpoint inhibitors in patients with HIV, tuberculosis, or underlying autoimmune diseases.
Aguilar-Company J; Lopez-Olivo MA; Ruiz-Camps I
Front Med (Lausanne); 2022; 9():875910. PubMed ID: 35911382
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
Ladouceur A; Barnetche T; Mouterde G; Tison A; Bitoun S; Prey S; Dutriaux C; Gerard E; Pham-Ledard A; Beylot-Barry M; Zysman M; Veillon R; Domblides C; Daste A; Gross-Goupil M; Sionneau B; Lefort F; Larroquette M; Richez C; Truchetet ME; Schaeverbeke T; Kostine M
RMD Open; 2023 Nov; 9(4):. PubMed ID: 38030233
[TBL] [Abstract][Full Text] [Related]
27. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
[TBL] [Abstract][Full Text] [Related]
28. Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment.
Braun D; Getahun D; Chiu VY; Coleman AL; Holland GN; Yu F; Gordon LK; Sun MM
Am J Ophthalmol; 2021 Apr; 224():282-291. PubMed ID: 33359682
[TBL] [Abstract][Full Text] [Related]
29. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
30. Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event.
Ye C; Lee K; Leslie WD; Lin M; Walker J; Kolinsky M
Osteoporos Int; 2023 Apr; 34(4):735-740. PubMed ID: 36729143
[TBL] [Abstract][Full Text] [Related]
31. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
Zhou L; Wei X
Front Immunol; 2021; 12():701951. PubMed ID: 34504488
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
33. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
Fortes BH; Liou H; Dalvin LA
Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
[TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.
Aoun R; Gratch D; Kaminetzky D; Kister I
Curr Neurol Neurosci Rep; 2023 Nov; 23(11):735-750. PubMed ID: 37870664
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies.
Sakakida T; Ishikawa T; Chihara Y; Harita S; Uchino J; Tabuchi Y; Komori S; Asai J; Narukawa T; Arai A; Tsunezuka H; Kosuga T; Konishi H; Moriguchi M; Yasuda H; Hongo F; Inoue M; Hirano S; Ukimura O; Itoh Y; Taguchi T; Takayama K
Clin Transl Oncol; 2020 Jun; 22(6):919-927. PubMed ID: 31576495
[TBL] [Abstract][Full Text] [Related]
36. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.
Byeon S; Cho JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Med; 2020 Apr; 9(7):2352-2362. PubMed ID: 32027780
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma.
Loriot Y; Sternberg CN; Castellano D; Oosting SF; Dumez H; Huddart R; Vianna K; Alonso Gordoa T; Skoneczna I; Fay AP; Nolè F; Massari F; Brasiuniene B; Maroto P; Fear S; Di Nucci F; de Ducla S; Choy E
Eur J Cancer; 2020 Oct; 138():202-211. PubMed ID: 32905959
[TBL] [Abstract][Full Text] [Related]
38. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
[TBL] [Abstract][Full Text] [Related]
39. Immune Checkpoint Inhibitors and Lupus Erythematosus.
Vitzthum von Eckstaedt H; Singh A; Reid P; Trotter K
Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399467
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study.
Da Silva Lopes AM; Colomer-Lahiguera S; Mederos Alfonso N; Aedo-Lopez V; Spurrier-Bernard G; Tolstrup LK; Pappot H; Aspeslagh S; Rogiers A; Neyns B; Haanen JB; Mitchell SA; Addeo A; Michielin O; Eicher M
Eur J Cancer; 2021 Nov; 157():225-237. PubMed ID: 34536946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
